izpis_h1_title_alt

Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer
ID Milevoj, Nina (Avtor), ID Tozon, Nataša (Avtor), ID Ličen, Sabina (Avtor), ID Lampreht Tratar, Urša (Avtor), ID Serša, Gregor (Avtor), ID Čemažar, Maja (Avtor)

URLURL - Izvorni URL, za dostop obiščite https://onlinelibrary.wiley.com/doi/epdf/10.1002/vms3.232 Povezava se odpre v novem oknu

Izvleček
The aim of this study was to evaluate the owners' perception of health-related qual- ity of life (HRQoL) of dogs after treatment with electrochemotherapy (ECT) alone or combined with interleukin-12 gene electrotransfer (IL-12 GET) and/or surgery. The owners of 44 dogs with histologically different tumours were offered the »Cancer Treatment Form« at least one month after treatment. The owners assessed their dogs’ quality of life (QoL) after treatment as good (mean 7.4) (from 1–very poor to 10–excellent) and the general health compared with the initial diagnosis of cancer as improving (mean 3.9) (from 1–worse to 5–better). The assessment of the current QoL was better within the group of dogs treated with non-invasive treatment (ECT and/ or IL-12 GET only), compared with those that received invasive treatment, where, in addition to ECT and/or IL-12 GET, surgery was performed (p < .05). The owners of dogs that achieved an objective response (OR) to the treatment assessed the QoL as significantly better compared with those whose dogs did not respond to the treat- ment (p < .05). The majority of the owners (86.4%) would opt for the therapy again, regardless of the financial costs. In conclusion, the results of this study demonstrate that the majority of the owners of dogs assessed their dogs’ QoL as good and felt that it improved after the treatment, especially in dogs, treated with non-invasive treatment and in those that responded to the treatment. This supports further use of ECT and IL-12 GET as suitable methods for the treatment of selected tumours in veterinary medicine.

Jezik:Angleški jezik
Ključne besede:Dogs, electrochemotherapy, gene electrotransfer, health, interleukin-12
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:VF - Veterinarska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2020
Št. strani:Str. 1-9
Številčenje:Vol. 6
PID:20.500.12556/RUL-116657 Povezava se odpre v novem oknu
UDK:636.09:602.6/7
ISSN pri članku:2053-1095
DOI:10.1002/vms3.232 Povezava se odpre v novem oknu
COBISS.SI-ID:4920442 Povezava se odpre v novem oknu
Datum objave v RUL:01.06.2020
Število ogledov:1277
Število prenosov:181
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Veterinary medicine and science
Skrajšan naslov:Vet. med. sci.
Založnik:J. Wiley & Sons
ISSN:2053-1095
COBISS.SI-ID:525255961 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:01.06.2020

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0003
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P4-0053
Naslov:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-6796
Naslov:Translacijska onkologija: razvoj in validacija imunsko genske terapije z interleukinom-12 v kombinaciji s kirurgijo pri oralnih in kožnih tumorjih psov

Financer:Drugi - Drug financer ali več financerjev
Program financ.:COST Action - European Regional Development Fund
Številka projekta:TD 1104

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj